The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

EMSHAPE ® NEO PLUS provides a comprehensive solution that targets fat reduction and muscle strengthening, while also ...

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

DoseSpot, which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today the results of a new data analysis on 102, ...

US Bancorp (NYSE:USB) is one of the 10 Cheap Large Cap Stocks to Buy According to Hedge Funds. On July 7, HSBC maintained a ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...